Stocks to Watch 10-11-11

CXM, UNVC, AFPW, OXGN, WH, NXOI

Our Stocks to Watch tomorrow include Cardium Therapeutics (NYSE Amex: CXM), Univec Inc. (OTC: UNVC), AlumiFuel Power Corp. (OTCBB: AFPW), OXiGENE Inc. (Nasdaq: OXGN), WSP Holdings Ltd. (NYSE: WH) and Next One Interactive Inc. (NXOI).

CARDIUM THERAPEUTICS INCORPORATED (AMEX: CXM)
"Up 222.92% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CXM.php

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen™ topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.

CXM News:

October 10 - Cardium Announces FDA 510(k) Clearance for U.S. Marketing and Sale of Excellagen Formulated Collagen Topical Gel for Diabetic Foot Ulcers, Pressure Ulcers and Other Dermal Wounds

Professional-Use, Sterile, Syringe-Based Topical Gel: Outcomes-Focused Wound Care Management

Cardium Therapeutics (NYSE Amex: CXM) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds. Directions for use indicate the application of Excellagen immediately following surgical debridement, which is routinely practiced in the treatment of diabetic foot ulcers and

Excellagen is a highly-refined fibrillar flowable bovine collagen topical gel (2.6%) that will initially be marketed as a sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers following surgical debridement procedures. In addition to diabetic foot ulcers, Excellagen is also cleared for use in the management of other dermal wounds including partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.

The Company believes that Excellagen provides a new sterile, syringe-based advanced wound care option as there are no other collagen-based wound management products available for professional use in the United States that are considered comparable to Excellagen in terms of its overall formulation, fibrillar nature and product format. Other professional use collagen-based products include granulated collagens that require mixing prior to use, as well as a variety of sheet-based products.

Cardium's Excellagen fibrillar collagen topical gel also represents a new technology and product platform that allows for the potential development of a portfolio of other advanced wound care and therapeutic products. Cardium's Gene Activated Matrix (GAM) technology represents one extension of Cardium's newly FDA-cleared flowable, fibrillar collagen-based matrix for the localized topical delivery of agents that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media. The Excellagen product is based on Cardium's newly-established manufacturing process, which allows for sterile fill of ready-to-use, single-use syringes for topical application. In addition, the advancement of Excellagen provides the opportunity to perform post-clearance studies to pursue therapeutic claims for the treatment of non-healing diabetic foot and pressure ulcers, as well as other wounds, following findings from Cardium's Matrix clinical study which showed that formulated collagen can significantly accelerate reductions in wound radius immediately following application compared to standard of care therapy in diabetic foot ulcers, and can support platelet activation and release of the wound healing protein, Platelet-Derived Growth Factor (PDGF).

"This FDA regulatory clearance is a significant milestone for Cardium and represents an important step forward in the advancement of our Excellagen technology platform, which we developed and commercially advanced following Cardium's acquisition of the Tissue Repair Company. We look forward to the launch of Excellagen and to helping address the large and rapidly-growing advanced wound care market. We are continuing to work with potential new collaborative partners and exploring additional product opportunities for our Excellagen formulation and additional advanced wound care products that could be based on the Excellagen technology platform. We recently posted an investor presentation on Excellagen to our website. The business focus of our portfolio is centered on health sciences and regenerative medicine and we look forward to initiating the late-stage/registration Aspire clinical study for our Generx® angiogenic therapy as a potential new treatment option for patients with myocardial ischemia due to advanced coronary disease," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

ABOUT EXCELLAGEN

UNIVEC INCORPORATED (OTC: UNVC)
"Up 71.43% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/UNVC.php

Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.

UNVC News:

September 23 - Univec Inc. Files Form 8-K

On September 1, 2010, Univec Inc. (OTC: UNVC) entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with AJW Partners, LLC, AJW Partners II, LLC, New Millennium Capital Partners III, LLC, AJW Master Fund, Ltd. and AJW Master Fund II, Ltd. (collectively, the "Investors"). Under the terms of the Securities Purchase Agreement, the Investors purchased an aggregate of $60,000 in 12% callable convertible secured notes (the "Notes").

For more information, visit http://bit.ly/nAnZHx.

ALUMIFUEL POWER CORPORATION (OTCBB: AFPW)
"Up 13.85% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/AFPW.php

AlumiFuel Power Corporation operates through its wholly owned subsidiary, AlumiFuel Power, Inc., a Philadelphia-based early production stage alternative energy company that generates hydrogen gas and steam for multiple applications requiring on-site, on-demand fuel sources.

AFPW News:

October 7 - AlumiFuel Power, Inc. Provides Rationale for Why the PBIS-2000 Portable Balloon Inflation System Technology Can Become the Worldwide Lift Gas Standard

Early production stage hydrogen generation company AlumiFuel Power, Inc. ("API"), the Philadelphia, Pennsylvania-based wholly owned operating subsidiary of AlumiFuel Power Corporation (OTCBB: AFPW) (the "Company"), revealed why the PBIS-2000 system can become a global standard following the award of the U.S. Air Force Special Operations Command (AFSOC) contract announced yesterday. Military and meteorological users from the US, NATO, and around the world have been following API's Portable Balloon Inflation System product development with keen interest, and have indicated that the technology embedded in the PBIS-2000 could offer a superior solution to lift gas requirements in remote and inaccessible locations.

The PBIS-2000 expands the capability of API's current family of hydrogen generators, which includes the PBIS-1000 (for 100g balloons) and the PBIS-lite (designed for 30g pilot balloons). The PBIS-2000 generates sufficient hydrogen to inflate a 200g weather balloon within 20 minutes using up to 6 AlumiFuel Cartridges contained in a single reactor vessel. The system operates at ambient temperature and pressure so that the user never has to deal with a high pressure system such as the industry standard K-Cylinder. After purchasing any unit of the PBIS family, typical customers continue to purchase replacement cartridges to launch up to 700 balloons per unit each year (up to 4,200 cartridges).

The current addressable weather balloon lift gas market is estimated at $150-$200 million per year, and encompasses military as well as civil government meteorological users worldwide. Traditionally, helium has been used as the primary lift gas for weather balloons, but with the increasing scarcity and cost of helium, users are rapidly switching to hydrogen and API's PBIS family is far more mobile, safe, cost effective and cheaper to maintain than other on-site hydrogen generation systems. The cost, complexity, and safety of the hydrogen supply chain is greatly improved because no hydrogen is transported or stored. An on-site water source of any quality can be used to generate the hydrogen in the PBIS system. Certain meteorological users have indicated that the use of the PBIS and AlumiFuel cartridges for the launching of two weather balloons daily from each of its sites would be only one-third the cost of hydrogen K-Cylinders delivered to various launching sites — an annual savings of over $120,000 per site, not to mention the avoidance of having to distribute and handle the awkward, heavy, high pressure K-Cylinders. In fact, users are now able to launch weather balloons from sites previously not accessible to K-Cylinders.

Moreover, the technology and configuration of PBIS systems provide an additional capability beyond balloon launching. PBIS units in the field also give users an added benefit by creating a ready-made logistics supply chain for hydrogen to power fuel cells. The 99.99+% purity of the hydrogen, as verified by an independent research lab, makes it ideally suited for fuel cells serving remote and man-portable power applications. Integrated with a fuel cell, two AlumiFuel cartridges could provide nearly 600Wh of electricity, resulting in a unique "hydrogen genset." API and its portable power partner, Ingenium Technologies of Rockford, Illinois, are pursuing back-up power market opportunities.

API's President & CEO, Mr. David Cade, said, "The advanced technology of the PBIS-2000 can be engineered into all of the PBIS family products, providing even more flexibility, user-friendliness, and rapid launching than current hydrogen lift gas systems, as well as cheaper and safer logistics. For these reasons, API believes the PBIS family can become the field standard and lift gas product of choice for NATO military users and meteorological customers worldwide."

OXIGENE INCORPORATED (NASDAQ: OXGN)
"Up 0.99% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/OXGN.php

OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.

OXGN News:

August 3 - OXiGENE Reports Second Quarter 2011 Financial Results

OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report second quarter 2011 results on Wednesday, August 10, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EDT (1:30 p.m. PDT).

To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations."

OXiGENE's earnings conference call can also be heard live by dialing (888) 841-3431 in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. EDT, (4:30 p.m. PDT) on August 10, 2011 and ending at midnight EDT (9:00 p.m. PDT) on Tuesday, August 16, 2011. To access the replay, please dial (855) 859-2056 if calling from the United States or Canada, or +1 (404) 537-3406 from international locations. Please refer to replay pass code 88795709.

WSP HOLDINGS LIMITED (NYSE: WH)
"Up 15.79% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/WH.php

WSP Holdings develops and manufactures seamless Oil Country Tubular Goods (OCTG), including seamless casing, tubing and drill pipes used for on-shore and off-shore oil and gas exploration, drilling and extraction, and other pipes and connectors. Founded as WSP China in 1999, the Company offers a wide range of API and non-API seamless OCTG products, including products that are used in extreme drilling and extraction conditions. The Company's products are used in China's major oilfields and are exported to oil producing regions throughout the world.

WH News:

October 4 - WSP Holdings Announces Conference Call to Discuss Second Quarter 2011 Results

WSP Holdings Limited (NYSE: WH) ("WSP Holdings" or the "Company"), a leading Chinese manufacturer of API (American Petroleum Institute) and non-API seamless casing, tubing and drill pipes used in oil and natural gas exploration, drilling and extraction ("Oil Country Tubular Goods" or "OCTG"), and other pipes and connectors, today announced that the Company will host a conference call at 9:00 a.m. Eastern Time on Tuesday October 11, 2011 to discuss its unaudited financial results for the second quarter of 2011.

NEXT 1 INTERACTIVE INCORPORATED (OTCBB: NXOI)
"Up 12.16% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/NXOI.php

Next One Interactive, Inc. (NXOI) is a multi faceted media company specializing in Travel and Real Estate. Next One plans the delivery of targeted content via multiple digital platforms including Satellite, Cable, Broadcast, Broadband and mobile. In today's digital market Next One Interactive delivers information and entertainment to consumers. The company business plan calls for multiple revenue streams from real estate and travel content delivery including transactional commissions, referral fees, advertising and sponsorship. The multiple revenue streams and integrated media platforms allow for the delivery of measurable return on investment to its advertisers, sponsors and business partners.

NXOI News:

October 6 - Real Estate Video On Demand Network Successfully Launched and Now Expanded to Three Additional Cities

Next 1 Interactive, Inc. (OTCBB: NXOI) announced that Next 1, in combination with its partner RealBiz Media, completed a flawless testing period of its "Home Tour Network" Video On Demand (VOD) platform in Los Angeles and Washington, D.C. The technical test launch passed with flying colors, resulting in 100% of the submitted local home listing videos and advertisements playing error free, on the Cable TV platform.

Passing the test phase with 100% success has allowed the Company to accelerate its intended path to roll out and has now gone live in three additional cities — Hartford, Providence, Rhode Island and San Diego — bringing the total cities operating in the Home Tour Network to five. The company is targeting Las Vegas and Phoenix in the coming months, as it works towards its ultimate goal of 100 cities nationwide by the end of 2012.

The Company is also pleased that the revenue model has gone into effect. As a result of passing this critical stage, the initial costing structure for showcasing 15-20 second property listing video on the Home Tour Network will be between $40 and $50 per month. The costing structure is based upon the Cable VOD market reach in each city. Our technology allows real estate brokers to automatically create 15-20 second home listing videos from their desktop on the fly. With a maximum of 1,000 listings per city, this platform should provide realtors who are early adopters a unique and affordable marketing advantage to showcase their property listings.

Furthermore, in addition to listing fees, the company will capture additional revenue from pre-roll and mid-roll advertising from real estate professionals and those industries interested in reaching consumers at or near their time of home transition.

"Based on our extensive experience creating visual marketing assets for real estate professionals over the last five years, it was obvious to us that the industry needs a new medium to reach consumers more efficiently and cost effectively. We are very confident that our vast business relationships in the trade will help us accelerate the adoption rate of this new and exciting media channel" says, Steve Marques, CEO of Home Tour Network VOD.

ABOUT REALBIZ MEDIA

RealBiz Media, Phoenix, Arizona, is the leading provider of rich media and image content delivery for the Real Estate Industry. RealBiz Media is focused on providing both integrated and interactive solutions for the seamless creation of High Resolution Media tours and videos for web and wireless. This technology allows automatic distribution to Franchise Corporations, MLS Associations and Search Engines like YouTube, Social Networks and TV. RealBiz Media's rich media content is supported by their (IPG) Image Processing Group delivering patented imaging technologies that are now being deployed in over 20 million digital cameras and mobile devices. RealBiz360 continues to add to its outstanding reputation as a technology leader in advanced imaging and content delivery and now has offices in Phoenix, AZ; Toronto, Canada and Baia Mare, Romania.